The Gross Margin of Ascendis Pharma A/S (ASND) is
86.82%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
86.82%
|
| 2024-12-31 |
87.83%
|
| 2023-12-31 |
83.36%
|
| 2022-12-31 |
76.28%
|
| 2021-12-31 |
54.76%
|
| Ticker |
Name |
Value |
|
BPMC
|
Blueprint Medicines Corp
|
96.04%
|
|
GLTO
|
Galecto Inc
|
7775.20%
|
|
SANA
|
Sana Biotechnology, Inc.
|
7775.20%
|
|
VIE
|
Viela Bio Inc
|
82.49%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
78.92%
|
|
GMAB.CO
|
Genmab A/S
|
93.60%
|
|
FGEN
|
FibroGen Inc
|
47.47%
|
|
FLUO.ST
|
Fluoguide AS
|
7775.20%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
83.62%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
98.31%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
69.33%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
93.45%
|
|
ZEAL.CO
|
Zealand Pharma A/S
|
99.99%
|
|
FATE
|
Fate Therapeutics Inc
|
7775.20%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
7775.20%
|
|
KOD
|
Kodiak Sciences Inc.
|
7775.20%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
9.32%
|
|
BAVA.CO
|
Bavarian Nordic A/S
|
48.83%
|
|
BHVN
|
Biohaven Ltd.
|
72.18%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
7775.20%
|
|
XLRN
|
Acceleron Pharma Inc
|
100.00%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
7775.20%
|
|
TGTX
|
TG Therapeutics, Inc.
|
83.66%
|
|
ORPHA.CO
|
Orphazyme A/S
|
7775.20%
|
|
IGMS
|
IGM Biosciences LLC
|
7775.20%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
34.28%
|
|
MRTX
|
Mirati Therapeutics Inc
|
95.18%
|
|
RVMD
|
Revolution Medicines, Inc.
|
7775.20%
|
|
SANION.ST
|
Saniona AB
|
78.93%
|
|
ALLR.ST
|
Allarity Therapeutics A/S
|
-175.91%
|
|
BIOPOR.CO
|
Bioporto A/S
|
75.44%
|
|
CCXI
|
Churchill Capital Corp XI
|
99.06%
|
|
CRSP
|
CRISPR Therapeutics AG
|
7775.20%
|
|
LEGN
|
Legend Biotech Corporation
|
60.34%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
89.81%
|